JP2021519076A5 - - Google Patents
Info
- Publication number
- JP2021519076A5 JP2021519076A5 JP2020551572A JP2020551572A JP2021519076A5 JP 2021519076 A5 JP2021519076 A5 JP 2021519076A5 JP 2020551572 A JP2020551572 A JP 2020551572A JP 2020551572 A JP2020551572 A JP 2020551572A JP 2021519076 A5 JP2021519076 A5 JP 2021519076A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutical composition
- agent
- psma
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024103109A JP2024123231A (ja) | 2018-03-29 | 2024-06-26 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650277P | 2018-03-29 | 2018-03-29 | |
| US62/650,277 | 2018-03-29 | ||
| PCT/US2019/025057 WO2019191728A1 (en) | 2018-03-29 | 2019-03-29 | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103109A Division JP2024123231A (ja) | 2018-03-29 | 2024-06-26 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519076A JP2021519076A (ja) | 2021-08-10 |
| JP2021519076A5 true JP2021519076A5 (https=) | 2022-04-06 |
| JP7512202B2 JP7512202B2 (ja) | 2024-07-08 |
Family
ID=66103056
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551572A Active JP7512202B2 (ja) | 2018-03-29 | 2019-03-29 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
| JP2024103109A Pending JP2024123231A (ja) | 2018-03-29 | 2024-06-26 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103109A Pending JP2024123231A (ja) | 2018-03-29 | 2024-06-26 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12059473B2 (https=) |
| EP (2) | EP3773910B1 (https=) |
| JP (2) | JP7512202B2 (https=) |
| KR (2) | KR102864931B1 (https=) |
| CN (2) | CN117924503A (https=) |
| AU (2) | AU2019245444B2 (https=) |
| BR (1) | BR112020019611A2 (https=) |
| CA (2) | CA3282900A1 (https=) |
| DK (1) | DK3773910T3 (https=) |
| ES (1) | ES2988767T3 (https=) |
| FI (1) | FI3773910T3 (https=) |
| HR (1) | HRP20241082T1 (https=) |
| HU (1) | HUE068337T2 (https=) |
| IL (2) | IL277357B2 (https=) |
| LT (1) | LT3773910T (https=) |
| MX (2) | MX2020010104A (https=) |
| PL (1) | PL3773910T3 (https=) |
| PT (1) | PT3773910T (https=) |
| RS (1) | RS66103B1 (https=) |
| SG (1) | SG11202009670RA (https=) |
| SI (1) | SI3773910T1 (https=) |
| SM (1) | SMT202400364T1 (https=) |
| WO (1) | WO2019191728A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3155519A1 (en) * | 2019-10-29 | 2021-05-06 | Steve Shih-Lin Huang | Psma-targeting imaging agents |
| EP4087855A1 (en) * | 2020-01-06 | 2022-11-16 | CytomX Therapeutics, Inc. | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
| JP2023547998A (ja) * | 2020-10-01 | 2023-11-15 | コーネル ユニバーシティー | 低分子リガンドの取り込み、内在化、及び／または保持を増加させるための方法及び組成物 |
| WO2022081443A2 (en) * | 2020-10-12 | 2022-04-21 | Memorial Sloan Kettering Cancer Center | Anti-psma antibodies and uses thereof |
| CA3198230A1 (en) * | 2021-01-28 | 2022-08-04 | Jian Chen | Conjugate and use thereof |
| WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
| WO2024178310A1 (en) | 2023-02-23 | 2024-08-29 | Ambrx, Inc. | Trop2-directed antibody-drug conjugates and uses thereof |
| CN120813607A (zh) * | 2023-02-28 | 2025-10-17 | 卫材R&D管理有限公司 | 抗psma抗体、缀合物和使用方法 |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| CN116196428B (zh) * | 2023-04-04 | 2025-04-04 | 上海愿智生物技术有限公司 | 一种药物组合物及其应用 |
| CN120835792A (zh) * | 2023-05-24 | 2025-10-24 | 杭州禧鹤生物科技有限公司 | 抗体-药物偶联物靶向治疗前列腺癌和其他肿瘤 |
| AU2024319528A1 (en) * | 2023-08-04 | 2026-02-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-psma antibody-drug conjugate and pharmaceutical use thereof |
| AU2024329469A1 (en) * | 2023-08-22 | 2026-04-09 | Ambrx, Inc. | Anti-psma adc conjugate compositions and methods of use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025184427A1 (en) * | 2024-02-27 | 2025-09-04 | Osteologic Therapeutics, Inc. | Bone-targeted antibodies and methods of use thereof |
| CN118754934B (zh) * | 2024-06-05 | 2025-02-07 | 浙江新码生物医药有限公司 | 一种用于制备药物偶联物的毒素衍生物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| ATE66469T1 (de) | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
| US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| AU2015203742B2 (en) * | 2007-06-26 | 2016-12-01 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| CN102159230A (zh) | 2008-07-23 | 2011-08-17 | Ambrx公司 | 经修饰的牛g-csf多肽和其用途 |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| CN108727466B (zh) * | 2012-06-07 | 2023-04-28 | Ambrx公司 | 前列腺特异性膜抗原抗体药物结合物 |
| CN104619350A (zh) * | 2012-06-14 | 2015-05-13 | Ambrx公司 | 结合到核受体配体多肽的抗psma抗体 |
| WO2015051199A2 (en) * | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
| EP3464379B1 (en) * | 2016-06-06 | 2023-09-27 | Abzena (UK) Limited | Antibodies, uses thereof and conjugates thereof |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| PL3630977T3 (pl) | 2017-06-02 | 2024-06-24 | Ambrx, Inc. | Sposoby i kompozycje promujące produkcję białek zawierających nienaturalne aminokwasy |
-
2019
- 2019-03-29 MX MX2020010104A patent/MX2020010104A/es unknown
- 2019-03-29 DK DK19717173.9T patent/DK3773910T3/da active
- 2019-03-29 CA CA3282900A patent/CA3282900A1/en active Pending
- 2019-03-29 LT LTEPPCT/US2019/025057T patent/LT3773910T/lt unknown
- 2019-03-29 WO PCT/US2019/025057 patent/WO2019191728A1/en not_active Ceased
- 2019-03-29 PL PL19717173.9T patent/PL3773910T3/pl unknown
- 2019-03-29 SG SG11202009670RA patent/SG11202009670RA/en unknown
- 2019-03-29 BR BR112020019611-8A patent/BR112020019611A2/pt unknown
- 2019-03-29 PT PT197171739T patent/PT3773910T/pt unknown
- 2019-03-29 US US17/042,838 patent/US12059473B2/en active Active
- 2019-03-29 KR KR1020207030091A patent/KR102864931B1/ko active Active
- 2019-03-29 JP JP2020551572A patent/JP7512202B2/ja active Active
- 2019-03-29 IL IL277357A patent/IL277357B2/en unknown
- 2019-03-29 FI FIEP19717173.9T patent/FI3773910T3/fi active
- 2019-03-29 KR KR1020257031656A patent/KR20250141858A/ko active Pending
- 2019-03-29 HU HUE19717173A patent/HUE068337T2/hu unknown
- 2019-03-29 AU AU2019245444A patent/AU2019245444B2/en active Active
- 2019-03-29 EP EP19717173.9A patent/EP3773910B1/en active Active
- 2019-03-29 RS RS20241125A patent/RS66103B1/sr unknown
- 2019-03-29 IL IL320375A patent/IL320375A/en unknown
- 2019-03-29 CN CN202410093812.9A patent/CN117924503A/zh active Pending
- 2019-03-29 SM SM20240364T patent/SMT202400364T1/it unknown
- 2019-03-29 ES ES19717173T patent/ES2988767T3/es active Active
- 2019-03-29 EP EP24190121.4A patent/EP4461318A3/en active Pending
- 2019-03-29 CN CN201980025915.9A patent/CN111989138B/zh active Active
- 2019-03-29 SI SI201930799T patent/SI3773910T1/sl unknown
- 2019-03-29 HR HRP20241082TT patent/HRP20241082T1/hr unknown
- 2019-03-29 CA CA3094985A patent/CA3094985C/en active Active
-
2020
- 2020-09-25 MX MX2024007724A patent/MX2024007724A/es unknown
-
2024
- 2024-06-26 JP JP2024103109A patent/JP2024123231A/ja active Pending
- 2024-07-01 US US18/761,130 patent/US20240350835A1/en active Pending
-
2025
- 2025-06-26 AU AU2025204809A patent/AU2025204809A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519076A5 (https=) | ||
| FI3773910T3 (fi) | Humanisoituja eturauhasspesifisen membraaniantigeeni (psma) -vasta-aineen ja lääkkeen konjugaatteja | |
| JP2015534578A5 (https=) | ||
| JP2018537975A5 (https=) | ||
| JP2015534577A5 (https=) | ||
| JP2008546792A5 (https=) | ||
| JP2013100314A5 (https=) | ||
| JP2019031565A5 (https=) | ||
| JP2015534579A5 (https=) | ||
| JP2013518912A5 (https=) | ||
| JP2017110002A5 (https=) | ||
| JP2003528924A5 (https=) | ||
| JP2021505540A5 (https=) | ||
| JP2017507931A5 (https=) | ||
| WO2005044307A3 (en) | Methods of therapy for b cell-related cancers | |
| JP2015531750A5 (https=) | ||
| JP2021528423A5 (https=) | ||
| JP2019500327A5 (https=) | ||
| JP2007515469A5 (https=) | ||
| JP2017526698A5 (https=) | ||
| JP2006506441A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2010520280A5 (https=) | ||
| JP2022513684A5 (https=) | ||
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 |